Marvell Technology (MRVL)
(Delayed Data from NSDQ)
$63.99 USD
-0.36 (-0.56%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $64.10 +0.11 (0.17%) 6:40 PM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
MRVL 63.99 -0.36(-0.56%)
Will MRVL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MRVL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRVL
Why Marvell Technology (MRVL) Dipped More Than Broader Market Today
The Zacks Analyst Blog Highlights Advanced Micro Devices, NVIDIA, Micron Technology and Marvell Technology
MRVL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Bulls Look Optimistic About Marvell (MRVL): Should You Buy?
Should Vanguard Extended Market ETF (VXF) Be on Your Investing Radar?
Do More U.S. Restrictions on China Make AMD a Risky Bet?
Other News for MRVL
MRVL September 6th Options Begin Trading
Marvell Announces Immediate Availability of Open Ecosystem Software for Teralynx 10 51.2T Switch
Marvell Teralynx 10 51.2T Ethernet Switch Enters Volume Production for Global AI Cloud Deployments
Marvel Biosciences Grants Stock Options to Leadership
Marvel Biosciences Expands Rett Syndrome Drug Research